Composite outcomes-final comment for now...

Journal of Clinical Epidemiology

Volumn 60, Issue 7, 2007, Pages 662-

  Freemantle, Nick ^a   Calvert, Melanie ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EVALUATION; CLINICAL STUDY; COMPOSITE OUTCOME; CONCEPTUAL FRAMEWORK; HAZARD RATIO; INCIDENCE; NOTE; OUTCOME ASSESSMENT; PATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 34250199722     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2006.12.005     Document Type: Note

References (3)

1. FDA Draft Guidance for Industry. Patient reported outcome measures: use in medical product development to support labeling claims (2006), FDA Draft Guidance for Industry. http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf Accessed January 16, 2007
2. The DREAM (Diabetes reduction Assessment with ramipril and rosiglitazone medication) Trial Investigators. Effect of rosiglitzone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (September 15, 2006) 10.1016/S0140-6736(06)69420-8
3. Freemantle N., Calvert M., Wood J., Eastaugh J., and Griffin C. Composite outcomes in randomized trials-greater precision but with greater uncertainty?. J Am Med Assoc 289 (2003) 2554-2559